Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at ...

Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to ...

A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Contributing: Ken Alltucker This article originally appeared on USA TODAY: Novo Nordisk: Wegovy, Ozempic prices fell in the first quarter ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

Trump threatened "very high" tariffs on Denmark amid Greenland dispute, raising fears of higher prices for Danish pharmaceuticals.

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.